Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials
Among individuals with overweight or obesity, GLP-1RAs and co-agonists were associated with a lower risk of incident AF event. This cardioprotective benefit may, at least in part, operate independently of the magnitude of weight loss.
Authors
- Christos Socrates Mantzoros (ORCID: https://orcid.org/0000-0003-3755-8158)
- Konstantinos C. Siontis (ORCID: https://orcid.org/0000-0002-6658-0971)
- Konstantinos Vlachos (ORCID: https://orcid.org/0000-0002-7543-3236)
- Antonios P. Antoniadis (ORCID: https://orcid.org/0000-0002-6604-5581)
- Paschalis Karakasis (ORCID: https://orcid.org/0000-0002-3561-5713)
- Dimitrios Patoulias
- Nikolaos Fragakis
Institutions
- Beth Israel Deaconess Medical Center (US)
- Aristotle University of Thessaloniki (GR)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Metabolism
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1016/j.metabol.2025.156463
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 10.36